Headline News

 

ViiV Healthcare announces FDA approval of Cabenuva, the first and only complete long-acting regimen for HIV treatment

Posted on January 26, 2021

First Extended-Release, Injectable Drug Regimen for Adults Living with HIV approved by FDA

Posted on January 26, 2021

Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants

Posted on January 26, 2021

First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda

Posted on January 26, 2021

Janssen Announce FDA Approval of CABENUVA, the First Long-Acting Regimen for the Treatment of HIV

Posted on January 26, 2021

Publication of Results from BENEFIT Study of MONARCH® Platform in CHEST Announced by Auris Health

Posted on January 26, 2021

U.S. FDA Approves OPDIVO® in Combination with CABOMETYX® as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

Posted on January 26, 2021

BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma approved by European Commission

Posted on January 26, 2021

Calquence approved for the treatment of relapsed or refractory chronic lymphocytic leukaemia in Japan

Posted on January 26, 2021

Symbicort Turbuhaler approved as an anti-inflammatory reliever in mild asthma in China

Posted on January 26, 2021

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

Posted on January 19, 2021

Positive efficacy data Presented by GSK of dostarlimab in mismatch repair-deficient solid cancers at ASCO Gastrointestinal Cancers Symposium

Posted on January 19, 2021

Collaboration announced by Novartis and GSK to support scientific research into genetic diversity in Africa

Posted on January 19, 2021

Novartis ligelizumab receives FDA Breakthrough Therapy designation for chronic spontaneous urticaria in patients

Posted on January 19, 2021

DARZALEX FASPRO® Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain Amyloidosis

Posted on January 19, 2021